Mark Denison Archives
Oct. 26, 2020—Researchers at Vanderbilt University Medical Center played a key role in the development of remdesivir, the first drug approved by the U.S. Food and Drug Administration for the treatment of COVID-19.
Jul. 14, 2020—An experimental coronavirus vaccine stimulated robust immune responses against SARS-CoV-2, the virus that causes COVID-19, and raised no serious safety concerns in an early-stage clinical trial.
Jul. 9, 2020—This week researchers at Vanderbilt University Medical Center (VUMC), the University of North Carolina at Chapel Hill and Gilead Sciences reported that remdesivir potently inhibited SARS-CoV-2, the virus which causes COVID-19, in human lung cell cultures and that it improved lung function in mice infected with the virus.
Apr. 16, 2020—The Medical Scientist Training Program has been intentional in approaching the challenges presented by COVID-19.
Apr. 6, 2020—Researchers at Vanderbilt University Medical Center are playing a key role in the development of a potential new antiviral drug to treat COVID-19.
Jul. 18, 2019—Mark Denison, MD, has been named director of the Division of Pediatric Infectious Diseases in the Vanderbilt Department of Pediatrics.
Jun. 29, 2017—A new antiviral drug candidate inhibits a broad range of coronaviruses, including the SARS and MERS coronaviruses, a multi-institutional team of investigators reports this week in Science Translational Medicine.
May. 12, 2016—Four physicians from Vanderbilt University Medical Center (VUMC) have been elected to membership in two of the nation’s oldest and most respected medical honor societies — the Association of American Physicians (AAP) and the American Society for Clinical Investigation (ASCI).
Feb. 18, 2016—The National Institutes of Health (NIH) has awarded Vanderbilt’s Department of Pediatrics a K12 training grant to support early career faculty to become physician-scientists, the first time the department has received such an award.
Nov. 12, 2012—Collaborating researchers at the University of North Carolina and Vanderbilt University have found that accelerating the rate of mutations in the coronavirus responsible for deadly severe acute respiratory syndrome (SARS) cripples the virus’s ability to cause disease in animals.